Accelerating DoD’s Fielding of Prototypes for Medical Countermeasures

Current Members
Funded to Date

Non-Traditional Members

Hands Icon


Prophylaxis, pretreatment, and post-exposure prophylaxis

Hospital Icon


Systems and devices to identify CBRN agents and assist in making medical decisions

Treat Icon


Therapeutics for post-exposure and post-symptomatic

The Medical CBRN Defense Consortium (MCDC) was formed in response to the Government’s expressed interest to establish an Other Transaction Agreement (OTA) with an eligible entity or group of entities, to include industry, academic, and not-for-profit partners, for advanced development efforts to support the Department of Defense’s (DoD) medical pharmaceutical and diagnostic requirements as related to enhancing the mission effectiveness of military personnel.


Companies that are part of the US Industrial base, as well as new and emerging non-traditional defense contractors, are encouraged to join the MCDC and participate in Federally-funded R&D projects.

  • Traditional Contractors
  • Non-Traditionals (Companies that don’t typically participate in Federal R&D)
  • Academia
  • Non-Profit/ Not-For-Profit Research Institutions

Led by

MCDC research and prototype work is executed by project teams from a broad-based industry/ academia collaboration.

Sponsored by

Joint Program Executive Office for Chemical and Biological Defense (JPEO-CBRND) Logo

Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense

Managed by

ATI: Advanced Technology International

Collaboration Management Firm Advanced Technology International (ATI)